In: Current Oncology Reports, 2021, vol. 23, no. 3, p. 10
Purpose of Review Richter syndrome (RS) is an uncommon but aggressive evolution of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). RS is an unmet clinical need in the field of CLL. Recent advances in understanding the biology of this condition provide the rationale for testing new therapeutic concepts in order to improve the outcome of patients developing RS, which is so far...
|
In: Oncogene, 2021, vol. 40, no. 7, p. 1205–1216
Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay of prostate cancer therapy. More potent inhibitors of androgen synthesis and antiandrogens have emerged and have been successfully i mplemented in clinical practice. That said, the stronger inhibition of the AR signaling axis has led in recent years to an increase of prostate cancers that de-differentiate...
|
In: Archives of Gynecology and Obstetrics, 2015, vol. 291, no. 6, p. 1387-1394
|
In: Supportive Care in Cancer, 2015, vol. 23, no. 2, p. 525-545
|
In: Clinical & Experimental Metastasis, 2015, vol. 32, no. 7, p. 677-687
|
In: Annals of Surgical Oncology, 2015, vol. 22, no. 3, p. 931-937
|
In: Supportive Care in Cancer, 2015, vol. 23, no. 2, p. 325-331
|
In: Leukemia, 2021, p. 7 p
The prognostic significance of lymphocyte doubling time (LDT) in chronic lymphocytic leukemia (CLL) was identified when the biology of the disease was poorly understood and therapy was not effective. We assessed the clinical and biological significance of LDT in 848 CLL patients in a real-life setting and the context of new biomarkers and effective therapy. A short LDT (≤12 months) was...
|
In: Haematologica, 2020, vol. 105, no. 2, p. 448-456
BIRC3 is a recurrently mutated gene in chronic lymphocytic leukemia (CLL) but the functional implications of BIRC3 mutations are largely unexplored. Furthermore, little is known about the prognostic impact of BIRC3 mutations in CLL cohorts homogeneously treated with first-line fludarabine, cyclophosphamide, and rituximab (FCR). By immunoblotting analysis, we showed that the non-canonical...
|
In: The breast, 2020, vol. 52, p. 110-115
Background: Corona Virus Disease 19 (COVID-19) had a worldwide negative impact on healthcare systems, which were not used to coping with such pandemic. Adaptation strategies prioritizing COVID-19 patients included triage of patients and reduction or re-allocation of other services. The aim of our survey was to provide a real time international snapshot of modifications of breast cancer...
|